Literature DB >> 9716022

Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo.

T D Bradshaw1, D F Shi, R J Schultz, K D Paull, L Kelland, A Wilson, C Garner, H H Fiebig, S Wrigley, M F Stevens.   

Abstract

2-(4-Aminophenyl)benzothiazole molecules substituted in the 3 position of the phenyl ring with a halogen atom or methyl moiety comprise a group of compounds that potently inhibit specific human ovarian carcinoma cell lines. GI50 values fall within the nM range. Inhibition is highly selective -- whereas the GI50 value in IGROV1 cells consistently lies at < 10 nM, SK-OV-3 presents GI50 values > 10 microM. Biphasic dose-response relationships were observed in sensitive cell lines after 48-h drug exposure. COMPARE analyses revealed the very similar profiles of anti-tumour activity of 3-substituted benzothiazoles and 5-(4-dimethylaminophenylazo)quinoline, with Pearson correlation coefficients > 0.65. Anti-tumour activity extended to preliminary in vivo tests. The growth of OVCAR-3 cells in polyvinylidene fluoride (PVDF) hollow fibres implanted in the peritoneal cavity of mice was inhibited by more than 50% after intraperitoneal (i.p.) administration of 2-(4-amino-3-methylphenyl)benzothiazole (10 mg kg(-1)), 2-(4-amino-3-chlorophenyl)benzothiazole (100 mg kg(-1)) or 2-(4-amino-3-bromophenyl)benzothiazole (150 mg kg(-1)). The growth of OVCAR-3 tumours in subcutaneously (s.c.) implanted hollow fibres was retarded by more than 50% after treatment with 2-(4-amino-3-methylphenyl)benzothiazole (6.7 and 10 mg kg(-1)). In addition, the growth of s.c. OVCAR-3 xenografts was delayed after exposure to DF 203. However, the relationship between drug concentration and growth inhibition was inverse.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9716022      PMCID: PMC2063080          DOI: 10.1038/bjc.1998.510

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  10 in total

1.  Antitumor benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo.

Authors:  D F Shi; T D Bradshaw; S Wrigley; C J McCall; P Lelieveld; I Fichtner; M F Stevens
Journal:  J Med Chem       Date:  1996-08-16       Impact factor: 7.446

2.  Design and synthesis of potent antitumor 5,4'-diaminoflavone derivatives based on metabolic considerations.

Authors:  T Akama; H Ishida; Y Shida; U Kimura; K Gomi; H Saito; E Fuse; S Kobayashi; N Yoda; M Kasai
Journal:  J Med Chem       Date:  1997-06-06       Impact factor: 7.446

3.  Characterization of two human ovarian carcinoma cell lines.

Authors:  G A Sinna; G Beckman; E Lundgren; I Nordenson; G Roos
Journal:  Gynecol Oncol       Date:  1979-06       Impact factor: 5.482

Review 4.  The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.

Authors:  A Monks; D A Scudiero; G S Johnson; K D Paull; E A Sausville
Journal:  Anticancer Drug Des       Date:  1997-10

5.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Authors:  A Monks; D Scudiero; P Skehan; R Shoemaker; K Paull; D Vistica; C Hose; J Langley; P Cronise; A Vaigro-Wolff
Journal:  J Natl Cancer Inst       Date:  1991-06-05       Impact factor: 13.506

6.  An information-intensive approach to the molecular pharmacology of cancer.

Authors:  J N Weinstein; T G Myers; P M O'Connor; S H Friend; A J Fornace; K W Kohn; T Fojo; S E Bates; L V Rubinstein; N L Anderson; J K Buolamwini; W W van Osdol; A P Monks; D A Scudiero; E A Sausville; D W Zaharevitz; B Bunow; V N Viswanadhan; G S Johnson; R E Wittes; K D Paull
Journal:  Science       Date:  1997-01-17       Impact factor: 47.728

7.  Structural studies on bioactive compounds. 23. Synthesis of polyhydroxylated 2-phenylbenzothiazoles and a comparison of their cytotoxicities and pharmacological properties with genistein and quercetin.

Authors:  M F Stevens; C J McCall; P Lelieveld; P Alexander; A Richter; D E Davies
Journal:  J Med Chem       Date:  1994-05-27       Impact factor: 7.446

8.  Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary.

Authors:  A P Wilson
Journal:  J Natl Cancer Inst       Date:  1984-03       Impact factor: 13.506

9.  Primary bioassay of human tumor stem cells.

Authors:  A W Hamburger; S E Salmon
Journal:  Science       Date:  1977-07-29       Impact factor: 47.728

10.  2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity.

Authors:  T D Bradshaw; S Wrigley; D F Shi; R J Schultz; K D Paull; M F Stevens
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

  10 in total
  11 in total

1.  Characterization of the 4-(benzothiazol-2-yl)phenylnitrenium ion from a putative metabolite of a model antitumor drug.

Authors:  Mrinal Chakraborty; Kyoung Joo Jin; Stephen A Glover; Michael Novak
Journal:  J Org Chem       Date:  2010-08-06       Impact factor: 4.354

2.  The Synthesis, Characterization, Molecular Docking and In Vitro Antitumor Activity of Benzothiazole Aniline (BTA) Conjugated Metal-Salen Complexes as Non-Platinum Chemotherapeutic Agents.

Authors:  Md Kamrul Islam; Seongmin Ha; Ah-Rum Baek; Byeong-Woo Yang; Yeoun-Hee Kim; Hyun-Jin Park; Minsup Kim; Sung-Wook Nam; Gang-Ho Lee; Yongmin Chang
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-15

3.  Chemistry of ring-substituted 4-(benzothiazol-2-yl)phenylnitrenium ions from antitumor 2-(4-aminophenyl)benzothiazoles.

Authors:  Yang Zhang; Mrinal Chakraborty; Christian G Cerda-Smith; Ryan N Bratton; Natalie E Maurer; Ethan M Senser; Michael Novak
Journal:  J Org Chem       Date:  2013-07-01       Impact factor: 4.354

4.  Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445).

Authors:  T D Bradshaw; M S Chua; S Orr; C S Matthews; M F Stevens
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

5.  In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles.

Authors:  T D Bradshaw; M-S Chua; H L Browne; V Trapani; E A Sausville; M F G Stevens
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

6.  The antitumour activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole in human gastric cancer models is mediated by AhR signalling.

Authors:  Yuling Wang; Ying Liu; Tao Tang; Ying Luo; Malcolm F G Stevens; Xi Cheng; Yan Yang; Dongfang Shi; Jihong Zhang; Tracey D Bradshaw
Journal:  J Cell Mol Med       Date:  2019-12-25       Impact factor: 5.310

7.  Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.

Authors:  C-O Leong; M Gaskell; E A Martin; R T Heydon; P B Farmer; M C Bibby; P A Cooper; J A Double; T D Bradshaw; M F G Stevens
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

8.  DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.

Authors:  V Trapani; V Patel; C-O Leong; H P Ciolino; G C Yeh; C Hose; J B Trepel; M F G Stevens; E A Sausville; A I Loaiza-Pérez
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

9.  Phthalimide Derivative Shows Anti-angiogenic Activity in a 3D Microfluidic Model and No Teratogenicity in Zebrafish Embryos.

Authors:  Annalisa Mercurio; Lucy Sharples; Filomena Corbo; Carlo Franchini; Angelo Vacca; Alessia Catalano; Alessia Carocci; Roger D Kamm; Andrea Pavesi; Giulia Adriani
Journal:  Front Pharmacol       Date:  2019-04-17       Impact factor: 5.810

10.  Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery.

Authors:  Alastair F Breen; David Scurr; Maria Letizia Cassioli; Geoffrey Wells; Neil R Thomas; Jihong Zhang; Lyudmila Turyanska; Tracey D Bradshaw
Journal:  Int J Nanomedicine       Date:  2019-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.